Spontaneous breaking of finite group symmetries at all temperatures
SciPost Physics · 22.06.2023 · 14 (6)
DOI: 10.21468/scipostphys.14.6.168 ↗Kurz gefasst
Fachartikel in der Zeitschrift SciPost Physics, online erschienen am 22.06.2023. Verfasst von Pedro Liendo und 2 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Huawei Technologies, Texas A and M University.
Abstract (Originalsprache)
We study conformal field theories with finite group symmetries with spontaneous symmetry breaking (SSB) phases which persist at all temperatures. We work with two \lambda \phi^4 λ ϕ 4 theories coupled through their mass terms. The two \lambda \phi^4 λ ϕ 4 theories are chosen to preserve either the cubic symmetry group, or the tetrahedral symmetry group. A one-loop calculation in the 4-\epsilon 4 − ϵ expansion shows that there exist infinitely many fixed points that can host an all temperature SSB phase. An analysis of the renormalization group (RG) stability matrix of these fixed points, reveals that their spectrum contains at least three relevant operators. In other words, these fixed points are tetracritical points.
Förderung
- Deutsche Forschungsgemeinschaft
- Huawei Technologies
- Texas A and M University
- United States Department of Energy
Zitieren
APA
Liendo, P., Rong, J., & Zhang, H. (2023). Spontaneous breaking of finite group symmetries at all temperatures. SciPost Physics, 14(6). https://doi.org/10.21468/scipostphys.14.6.168
Vancouver
Liendo P, Rong J, Zhang H. Spontaneous breaking of finite group symmetries at all temperatures. SciPost Physics. 2023;14(6). doi:10.21468/scipostphys.14.6.168
BibTeX
@article{Liendo2023,
author = {Liendo, Pedro and Rong, Junchen and Zhang, Haoyu},
title = {Spontaneous breaking of finite group symmetries at all temperatures},
journal = {SciPost Physics},
year = {2023},
volume = {14},
number = {6},
doi = {10.21468/scipostphys.14.6.168}
}
EUVIMED